IronBridge Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

IronBridge Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-2,638	Closed	-$401K	–	207
2014 Q1	$401K	Sell	2,638 -880	-25%	-$140K	0.01%	198
2013 Q4	$467K	Sell	3,518 -2,359	-40%	-$283K	0.01%	199
2013 Q3	$683K	Sell	5,877 -147,036	-96%	-$16.1M	0.01%	204
2013 Q2	$14.1M	Buy	+152,913	New	+$14.7M	0.28%	123

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

IronBridge Capital Management's ALXN Position: Q2 2014 in Review

IronBridge Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 2,638 shares — an estimated $401K sold.

IronBridge Capital Management first reported a position in ALXN in Q2 2013 and held it in 4 quarters. The position peaked at $14.1M in Q2 2013. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

IronBridge Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
IronBridge Capital Management sold 2,638 Alexion Pharmaceuticals shares in Q2 2014, an estimated $401K.
IronBridge Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
IronBridge Capital Management's Alexion Pharmaceuticals position peaked at $14.1M in Q2 2013.
521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on IronBridge Capital Management's 13F filing for Q2 2014, filed 11 Jul 2014.